RxDoctor Payments Data

Kevin Roe, DO

Nephrology · State College, PANPI 1538309174

Payments from drug & device makers

$755in general payments, 2019–2025

Across 35 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$153
  • AstraZeneca$103
  • Amgen$76
  • Mallinckrodt Enterprises LLC$75
  • Novartis$67
  • Otsuka America Pharmaceutical, Inc.$58
  • plus $223 from 9 others

What the payments were for

  • Food & beverage$68090%
  • Education$7510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$755 in reported general payments places this provider in the 50th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$131,651
Medicare patients
237
Services billed
2,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FabrazymeAgalsidase Beta26$470,228
JardianceEmpagliflozin75$73,250
FarxigaDapagliflozin Propanediol14$18,921
EliquisApixaban17$16,944
EntrestoSacubitril/Valsartan16$12,267
LokelmaSodium Zirconium Cyclosilicate14$10,043
Potassium Citrate ErPotassium Citrate51$6,074
Calcitriol143$3,083
Sevelamer Carbonate37$2,807
Cinacalcet Hcl13$2,771
Losartan Potassium140$1,868
Potassium Chloride78$1,766
Calcium Acetate18$1,645
Bumetanide26$1,527
Lisinopril75$902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiFabrazyme$32$470,22826 claims
Boehringer IngelheimJardiance$153$73,25075 claims
AstraZenecaFarxiga, Lokelma$103$28,96528 claims
NovartisEntresto$67$12,26716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →